"10.1371_journal.pone.0150084","plos one","2016-02-24T00:00:00Z","Susan P Foy; Barbara Sennino; Tracy dela Cruz; Joseph J Cote; Evan J Gordon; Felicia Kemp; Veronica Xavier; Alex Franzusoff; Ryan B Rountree; Stefanie J Mandl","Bavarian Nordic, Inc., Redwood City, California, United States of America","Conceived and designed the experiments: SPF BS AF RBR SJM. Performed the experiments: SPF BS TDC JJC EJG FK VX. Analyzed the data: SPF BS TDC JJC EJG FK VX. Wrote the paper: SPF BS AF RBR SJM.","The authors have the following interests: Some of the authors are inventors on two patents owned by Bavarian Nordic, Inc. that pertain to this article. Those patents are International Publication Number WO 2015/069571 A1, entitled “Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist and/or agonist of an immune checkpoint inhibitor” and WO 2015/175334 A2, entitled “Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist”. The authors Susan P. Foy, Barbara Sennino, Tracy dela Cruz, Joseph Cote, Evan J. Gordon, Felicia Kemp, Veronica Xavier, Alex Franzusoff, Ryan B. Rountree, and Stefanie J. Mandl were employed by Bavarian Nordic, Inc. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2016","02","Susan P Foy","SPF",10,TRUE,5,7,7,5,TRUE,TRUE,FALSE,0,NA,FALSE
